These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 26162965)

  • 1. New immunotherapies targeting the PD-1 pathway.
    Chinai JM; Janakiram M; Chen F; Chen W; Kaplan M; Zang X
    Trends Pharmacol Sci; 2015 Sep; 36(9):587-95. PubMed ID: 26162965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-PD-1 antibody: basics and clinical application].
    Tanaka Y; Okamura H
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1145-9. PubMed ID: 24047772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
    Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
    J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
    Fife BT; Bluestone JA
    Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 in disease.
    Kuol N; Stojanovska L; Nurgali K; Apostolopoulos V
    Immunotherapy; 2018 Feb; 10(2):149-160. PubMed ID: 29260623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 Pathway in Breast Cancer.
    Schütz F; Stefanovic S; Mayer L; von Au A; Domschke C; Sohn C
    Oncol Res Treat; 2017; 40(5):294-297. PubMed ID: 28346916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
    Hamid O; Carvajal RD
    Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer.
    Henick BS; Herbst RS; Goldberg SB
    Expert Opin Ther Targets; 2014 Dec; 18(12):1407-20. PubMed ID: 25331677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.
    Luo M; Fu L
    Oncotarget; 2016 May; 7(20):29794-803. PubMed ID: 26919108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
    Swaika A; Hammond WA; Joseph RW
    Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.
    Wang T; Wu X; Guo C; Zhang K; Xu J; Li Z; Jiang S
    J Med Chem; 2019 Feb; 62(4):1715-1730. PubMed ID: 30247903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of PD-1 in regulating T-cell immunity.
    Jin HT; Ahmed R; Okazaki T
    Curr Top Microbiol Immunol; 2011; 350():17-37. PubMed ID: 21061197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction.
    Gettinger S; Herbst RS
    Cancer J; 2014; 20(4):281-9. PubMed ID: 25098289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.
    Dolan DE; Gupta S
    Cancer Control; 2014 Jul; 21(3):231-7. PubMed ID: 24955707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
    Robert C; Soria JC; Eggermont AM
    Eur J Cancer; 2013 Sep; 49(14):2968-71. PubMed ID: 23907003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.